Category: biotechnology
In business, the decision to support an initiative is frequently made following a live presentation supported by slides. Too often these presentations miss the mark. Cruxio specializes in equipping biomedical companies to develop and deliver clear, powerful strategic stories - usually as live presentations. In the past four years, Cruxio's unique story-development methodology has fueled more than 50 mission-critical presentations, helping to secure more than $500 million in funds or revenue. Join Rob Wishnowsky, founder of Cruxio - the crux of the story - for an interactive overview of five essentials you need to consider to develop your clear, compelling strategic story.
In 2005 Rob Wishnowsky founded Cruxio (the crux of the story), a West Coast company that helps companies develop and deliver clear strategic stories. Cruxio's proprietary processes have been used in more than fifty presentations, securing more than $500 million in funding or revenue. Rob has extensive experience in global strategy, sales and marketing in the fields of life science, diagnostics and biotechnology. 20 years he has led business units, sales forces, strategy formulation, market segmentation, portfolio development and marketing execution, primarily in large corporations (Boehringer Mannheim/Roche Diagnostics, Johnson & Johnson's Lifescan) as well as in early-stage companies. He served on the board of the Biomedical Marketing Association from 2003 to 2007.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=206505
Participation comes from academic institutions and companies across the state
Waltham, Massachusetts - The Massachusetts Life Sciences Center’s 2010 Internship Challenge has received an overwhelming response since its February launch, with nearly 900 applicants seeking internships this summer. Over 130 companies from all sectors of the life sciences community have combed through hundreds of resumes, held numerous interviews, and selected interns to hire. Through the Challenge, 164 interns have been matched with 93 life sciences companies, a more than 50% increase from the 104 interns selected in 2009.
The Massachusetts Life Sciences Center’s Internship Challenge is a workforce development program focused on enhancing the talent pipeline for life sciences companies in Massachusetts while providing interns with practical, “hands on” experience that prepares them to step into the workforce ready to meet the job requirements of life sciences employers. The program is providing paid summer internships to undergraduates, graduate students, and recent college graduates from 46 different colleges and universities.
Applications to Present at Conference Now Accepted from Emerging Biotech, Medical Device and Healthcare Informatics Companies
LOS ANGELES--The Southern California Biomedical Council (SoCalBio) announced today that its 12th Annual Investor & Partnership Conference will be held on Thursday, November 4th at the JW Mariott Hotel at L.A. Live.
This year's conference carries the theme "Sustaining Innovation in a Challenging Economy," and will include sessions focused on how emerging companies can succeed when traditional sources of early stage funding are in short supply. As always, the conference will also showcase dynamic bioscience firms currently seeking capital and partnership opportunities.
Licensing and partnering are changing the face of biopharma. The formerly distinct pharmaceutical and biotechnology industries are merging into one interdependent Industry. Partnered products are the future of innovation leading to a significant increase in attempts to acquire and/or license innovation from others. Join industry speakers, Mervyn J. Turner, Ph.D., Chief Strategy Officer, Merck & Co. Inc. & Sr. Vice President, Emerging Markets, Merck Research Laboratories, Mark Edwards, President, Deloitte Recap, LLC, Barbara Ryan, Managing Director, Deutsche Bank, Faculty Leader, Dave Summa of Acumen Pharmaceuitcals, Keith Donnermeyer, Partner and National Life Sciences Sector Leader, Deloitte & Touche LLP, and others on Day 5 of the BioExec Institute 2010. Some topics include:
- Understand the microeconomic basis for the “20th Century” deal
- Discuss lessons learned from deals that happened and deals that didn’t
- Review recent trends in deals
- Understand three important macroeconomic trends and their implications for the next 10 years
- Discuss the need for a “21st Century” deal and recent examples
Center Awards $1.5 million to foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster
For Immediate Release: Date: May 28, 2010
Contact: Angus G. McQuilken, MLSC VP for Communications
Phone: (617) 921-7749 Email: amcquilken@masslifesciences.com
“This is all about jobs. By helping life sciences companies grow, we create new opportunities for people to work,” said Governor Deval Patrick. “As we continue to strengthen our global leadership in the life sciences, this program will meet an important need and make Massachusetts an even more attractive place for life sciences companies to locate and grow.”
Waltham, MA – The Massachusetts Life Sciences Center’s Board of Directors today awarded $1.5 million in Small Business Matching Grants to three life sciences companies in Massachusetts. The companies receiving grants are Boston Biochem Inc. and Tetragenetics Inc., both of Cambridge and Thermedical Inc. of Somerville. Each company will receive $500,000 from the Center to match federal small business grant funding that the companies had previously been awarded. The grants represent the first round of awards issued under the Center’s Small Business Matching Grant (SBMG) Program. The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York.
The Center’s Small Business Matching Grant Program, launched in January 2010 as part of the state’s ten-year, $1 billion Life Sciences Initiative, will match federal small business grant funding for early-stage life sciences companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Goals of the program include the creation of jobs in Massachusetts by the commercialization of products with high potential for market adoption and penetration.
 |
|
Intellectual Property Protection:
The Basics
|
|
qed@qb3 - Berkeley
Friday, June 6, 2010
12:00 to 1:00 pm
Stanley Hall Atrium
|
Protecting inventions and trade secrets is a basic requirement for technology start-ups. The process generally involves interfacing with the office of technology transfer of the University and patent attorneys. The legal jargon and patenting process can be daunting and is filled with pitfalls. Understanding the basics of IP protection is a fundamental requirement for all scientists and corporate officers. Once there is an invention, what steps must a start-up follow in order to secure patent protection. Dr. Joseph R. Snyder is a patent attorney and partner in the chemistry and biotechnology group of Townsend and Townsend and Crew. His presentation will focus on understanding the basic requirements for patenting a chemical or a biotechnical invention.
Dr. Joseph R. Snyder's practice emphasizes patent drafting, patent procurement, client counseling, and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies' commercial potential; in the enforcement of patent rights; and in the defense of infringement allegations. He conducts and performs due diligences investigations in connection with commercial transactions, such as mergers, acquisitions, and the establishment of strategic business alliances. These investigations involve intellectual property including patents, technology licenses, acquisition agreements, and asset purchase agreements. He also advises on the creation of start-ups and their patent portfolio development, coordinating the transfer and licensing of intellectual property as it relates to office of technology transfer agreements, collaborative/ sponsored research agreements, and other transfer agreements. He worked as a patent attorney for Zeneca Ag Products. Prior to becoming a patent attorney, he was a senior scientist in their analytical department. Joseph received a PhD in Chemistry from Notre Dame and a JD from USF.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=204217
- Sanofi-aventis Supports Consortium’s Activities to Fund Promising Early-Stage Life Sciences Companies -
Chicago, IL – May 5, 2010 – Sanofi-aventis and the Massachusetts Life Sciences Center (MLSC), a quasi-public agency tasked with implementing the State’s ten-year, $1 billion Life Sciences Initiative, announced that sanofi-aventis has joined the Center’s Corporate Consortium Program. The partnership was announced at the BIO International Convention, the largest global event for the biotechnology industry taking place this week in Chicago, Illinois.
Massachusetts Lieutenant Governor Timothy Murray joins life sciences leaders for ribbon-cutting ceremony
For Immediate Release: Date: 02/24/10
Contacts:
Massachusetts Life Sciences Center
Angus G. McQuilken, Vice President for Communications
Phone: 617-921-7749 Email: amcquilken@masslifesciences.com
WPI/Gateway Park
Michael Cohen
Phone: 508-868-4778 Email: mcohen@wpi.edu
Grant leverages $25 million private investment for development of a new facility that will create jobs, house young companies and provide training programs in the life sciences
Waltham, MA— The Massachusetts Life Sciences Center Board of Directors today awarded a $6.6 million grant to Worcester Polytechnic Institute (WPI) to support the next phase of life sciences related development at Gateway Park in Worcester. The grant leverages $25 million in private investment for the development of a new 80,000-square-foot life sciences facility anticipated to create 120 construction jobs and 142 new permanent jobs at completion.
The grant supports the development of WPI’s Biomanufacturing Education and Training Center (BETC); a new incubator for Massachusetts Biomedical Initiatives (MBI); and expanded academic and research space, including new facilities for the Massachusetts Academy of Math and Science. The BETC is planning a 10,000-square-foot facility that will provide hands-on biomanufacturing training to support industry workforce development. MBI is planning to expand its incubator resources by developing a new wet-lab core facility to help more companies launch, grow and provide jobs. MBI currently operates three life sciences incubators in Central Massachusetts (one of which is located in the first Gateway Park building) and has graduated 30 companies, creating 265 new jobs since 2000.
 |
|
Grantwriting 101
including SBIR and STTRs
|
|
qed@qb3 - UCB
Friday, February 5, 2010
12:00 to 1:00 pm
Stanley Hall Room 621
|
SBIR/STTR grants can provide the critical funding necessary to launch your company. But success requires mastering the tricks of the SBIR/STTR program, some of which have frustrated excellent groups. From where to register to uploading your proposal, we'll cover the ins and outs of preparing grants for the NIH. This seminar is aimed at new and experienced grantwriters, from academia and industry. Even veteran grantwriters will benefit from a review of the new formats required as of January 2010.
Shauna Farr-Jones has a 10-year record of writing successful government grant and contract proposals on diverse life science topics, providing strategic input on both research and business plans. She has helped companies secure over $125 million in grant and contract funding from government and philanthropic agencies. Previously, she was at BioCentury Publications, where she analyzed the biotechnology industry. She was a postdoc in PharmChem at UCSF after a Ph.D. in Biochem from Tufts.
Amy F. Boggs is an independent consultant with more than 8 years experience in grant-writing. She also handles the preparation of technical reports, INDs and NDAs, technology assessment, strategic research planning, and competitive landscaping. Prior, Dr. Boggs worked at Microcide and at IntraBiotics, where she managed an interdisciplinary technology in-licensing team. Dr. Boggs is an inventor on three issued patents and has worked on IND-enabling projects. She completed a Ph.D. in PharmChem at UCSF under Dr. Agard.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=197134
